Survodutide: Boehringer Ingelheim's GLP-1/Glucagon Dual Agonist for Weight Loss

A Different Kind of Dual Agonist

The GLP-1 drug class has transformed obesity medicine. Semaglutide (Wegovy) produces roughly 15% weight loss, and tirzepatide (Zepbound) pushes that to 20-22% by adding a second hormone pathway — GIP. Now Boehringer Ingelheim and Zealand Pharma are advancing a drug that takes a different second pathway entirely: glucagon.

Survodutide (BI 456906) is a once-weekly injectable GLP-1/glucagon receptor dual agonist. While it shares GLP-1 receptor activation with semaglutide and tirzepatide, its second target — the glucagon receptor — creates a meaningfully different metabolic profile. Glucagon drives the liver to burn stored fat and raises the body's basal metabolic rate, a mechanism with particular implications for patients with fatty liver disease alongside obesity.

Phase 3 results showing up to 19% body weight loss put survodutide firmly in competitive territory with existing approvals. Combined with its NASH/fatty liver benefits, survodutide could carve out a unique position in the obesity drug market — not just as another GLP-1, but as the preferred option for the large subset of obese patients who also carry excess liver fat. Learn about currently available GLP-1 treatments while survodutide completes its development.

Mechanism of Action: GLP-1 + Glucagon

To understand survodutide's advantage, it helps to understand what each receptor does when activated:

The critical insight is that GLP-1 and glucagon target complementary mechanisms. GLP-1 reduces calories in by suppressing appetite; glucagon increases calories out by raising metabolic rate and driving fat burning. Together, they create an energy deficit from both sides of the equation — a double-pronged approach that neither agent achieves alone.

This contrasts with tirzepatide's GLP-1/GIP combination, where both GIP and GLP-1 primarily act on appetite and insulin secretion. The glucagon pathway in survodutide adds metabolic acceleration that the GIP pathway does not provide. See how GLP-1 medications work for a foundational understanding of this drug class.

Phase 3 Clinical Trial Data

Survodutide vs Semaglutide, Tirzepatide, and Retatrutide

The obesity drug pipeline is becoming increasingly competitive. Here is how survodutide compares to its closest peers:

Survodutide and NASH/Fatty Liver Disease: A Deeper Look

Non-alcoholic steatohepatitis (NASH) — now more often called metabolic dysfunction-associated steatohepatitis (MASH) — is one of the fastest-growing liver diseases globally, affecting an estimated 15-20% of people with obesity. It progresses from simple fat accumulation (steatosis) through inflammation, fibrosis, cirrhosis, and in some cases liver failure or hepatocellular carcinoma.

The glucagon receptor plays a direct role in hepatic fat metabolism. When glucagon receptors in the liver are activated, hepatocytes increase fatty acid oxidation — essentially burning through the fat stored in liver cells. They also reduce lipogenesis (new fat production) and promote export of triglycerides. This mechanism operates independently of weight loss, meaning survodutide may reduce liver fat even in patients who have not yet lost substantial body weight.

Clinical trial data has demonstrated that survodutide-treated patients show:

• Significant reductions in liver fat fraction measured by MRI-PDFF
• Improvements in liver enzymes (ALT, AST), indicating reduced liver inflammation
• Histological improvement on liver biopsy in a meaningful proportion of NASH patients — including fibrosis regression
• Reductions in Enhanced Liver Fibrosis (ELF) score, a validated non-invasive marker of liver fibrosis

This positions survodutide as a dual-indication candidate: both an obesity treatment and a NASH/MASH therapy. Boehringer Ingelheim has filed for the NASH indication separately, which could lead to a broader label than pure obesity drugs carry. For clinicians managing patients with both conditions — an extremely common overlap — survodutide would simplify the treatment regimen considerably. Learn how current GLP-1 treatments support metabolic health.

Side Effects and Safety Profile

Survodutide's side effect profile shares most characteristics with the broader GLP-1 class, with a few noteworthy differences driven by its glucagon receptor component:

• Gastrointestinal effects: Nausea, vomiting, diarrhea, and decreased appetite are the most frequently reported side effects, especially during the dose-escalation phase. Most GI effects diminish after the first 4-8 weeks as the body adapts to the medication.
• Elevated heart rate: Glucagon receptor activation can modestly increase resting heart rate, a side effect that is less common with pure GLP-1 drugs. In trials, mean heart rate increases of approximately 5-8 bpm were observed. This is generally well-tolerated but is something to monitor in patients with pre-existing cardiac conditions.
• Hypoglycemia: Risk is low in patients without diabetes given the glucose-dependent nature of GLP-1 insulin secretion. Risk increases when combined with insulin or sulfonylurea medications.
• Gallbladder events: As with other GLP-1 class drugs, cholelithiasis (gallstones) has been reported at slightly elevated rates, likely related to rapid weight loss. Monitoring is recommended for patients with prior gallbladder issues.
• Injection site reactions: Mild redness or bruising at the injection site occurs in a small percentage of patients, consistent with other subcutaneous weekly injectables.

The overall discontinuation rate due to adverse events in Phase 3 trials was in line with other drugs in this class. The titration schedule — starting at a low dose and escalating over several weeks — is designed to minimize GI side effects and help patients tolerate the therapeutic dose.

Approval Timeline: What to Expect

Based on available information as of April 2026, here is the expected development timeline for survodutide:

While the timeline looks promising, drug development carries inherent uncertainty. Phase 3 trials can produce unexpected safety signals or fail to meet efficacy endpoints. Regulatory agencies may request additional data. Patients who need effective obesity treatment today should not wait for survodutide's potential approval. Explore treatments that are available right now.

Who Would Be an Ideal Survodutide Candidate?

While FDA labeling will define approved indications, the clinical trial data suggests survodutide may be particularly suited for:

• Patients with obesity plus NASH/MASH: The glucagon-driven liver benefit makes survodutide the most liver-directed option in the pipeline for this common dual diagnosis.
• Patients who did not achieve adequate weight loss on semaglutide: The glucagon metabolic acceleration may help patients who plateaued on GLP-1-only therapy.
• Patients with elevated triglycerides: The strong lipid-lowering and hepatic fat-reducing effects of glucagon receptor activation may offer additional cardiovascular benefit in this population.
• Patients seeking the highest weight loss without the complex triple-agonist profile: Survodutide's dual mechanism is simpler than retatrutide's triple agonism, which may translate to a more predictable side effect profile for some patients.

Survodutide may be less ideal for patients with a history of frequent hypoglycemia on current medications, those with significant arrhythmias (given the modest heart rate increase), or patients who cannot tolerate GI side effects typical of this drug class.

Available Now: Start GLP-1 Treatment While Waiting

Survodutide's arrival in 2027 or 2028 is not guaranteed, and even if it succeeds, the wait involves years of potential weight gain and compounding metabolic health consequences. The good news is that FDA-approved options available today — including both brand-name and compounded GLP-1 medications — already deliver life-changing results.

Trimi provides physician-supervised GLP-1 treatment with compounded semaglutide and tirzepatide, offering the same evidence-based approach used in landmark clinical trials. Patients who start treatment now and achieve 15-20% weight loss will be in a far better metabolic position when next-generation options like survodutide become available — and may not need them at all.

Starting GLP-1 treatment is straightforward: a brief online consultation, physician review, and if appropriate, medication prescribed and delivered directly to your door. You can get started with a Trimi consultation and have your first dose within days. There is no reason to delay effective treatment while waiting for drugs still in clinical trials.

When survodutide does receive approval, having already established GLP-1 tolerance and healthy habits may make transitioning to or adding newer options even more effective. Learn how Trimi's GLP-1 program works and what to expect in the first few months of treatment.

Frequently Asked Questions